Document ID: chunk:federal_register_of_legislation:F2022C00582:reg:9:p1
Version: federal_register_of_legislation:F2022C00582
Segment Type: reg
Provision Reference: reg 9 (pt 1/3)
Character Range: 5416–8453

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting immune thrombocytopaenia or death from immune thrombocytopaenia with the circumstances of a person's relevant service:
(1)          having a viral infection from the specified list of viral infections within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of viral infections is defined in the Schedule 1 - Dictionary.
(2)          having a bacterial or fungal infection from the specified list of bacterial and fungal infections, within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of bacterial and fungal infections is defined in the Schedule 1 - Dictionary.
(3)          being treated with a drug or a drug from a class of drugs from the specified list of drugs, within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(4)          receiving a vaccine from the specified list of vaccines within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of vaccines is defined in the Schedule 1 - Dictionary.
(5)          being treated with a drug or receiving a dose of vaccine which is associated in the individual with the following:
(a)          the development of immune thrombocytopaenia within six weeks of commencing drug therapy or receiving the dose of vaccine; and
(b)          an absence of immune thrombocytopaenia prior to commencing drug therapy or vaccination; and
(c)          sustained recovery from immune thrombocytopaenia on ceasing drug therapy or vaccination; and
(d)          exclusion of other aetiologies for thrombocytopaenia (including other drugs or vaccines);
(6)          being pregnant within the six weeks before the clinical onset of immune thrombocytopaenia;
(7)          having a lymphoproliferative disorder from the specified list of lymphoproliferative disorders, at the time of the clinical onset of immune thrombocytopaenia;
Note: specified list of lymphoproliferative disorders is defined in the Schedule 1 - Dictionary.
(8)          having an autoimmune or inflammatory disorder from the specified list of autoimmune and inflammatory disorders, at the time of the clinical onset of immune thrombocytopaenia;
Note: specified list of autoimmune and inflammatory disorders is defined in the Schedule 1 - Dictionary.
(9)          consuming a food or beverage from the specified list of food and beverages, within the six weeks before the clinical onset of immune thrombocytopaenia;
Note: specified list of food and beverages is defined in the Schedule 1 - Dictionary.
(10)      consuming a food or beverage which is associated in the individual with the following:
(a)          the development of immune thrombocytopaenia within six weeks of consuming the food or beverage; and
(b)          an absence of